Clinical trials: 18 Years and Over
Influenza
Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults
A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over. To assess the effect of MVA-NP+M1 on the reduction of laboratory confirmed influenza when given as an adjunct…
- Trial name
- NCT03880474
- Testing
- MVA-NP+M1, Saline
- Where
- 9 sites in Australia
- Volunteers
- 2,364 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Coronavirus Disease 2019
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
Popular topic：Clinical study of recombinant Novel Coronavirus vaccine (CHO cell) combined with influenza vaccine. Research purpose:Main purpose:To evaluate the immunogenicity of recombinant Novel Coronavirus vaccine (CHO cells)…
- Trial name
- NCT05107375
- Testing
- Tetravalent influenza virus lysis vaccine, Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 299 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
SARS-CoV-2
Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and Over
This is a single-center, randomized, blinded, placebo-controlled clinical trial to evaluate the protective efficacy, safety and immunogenicity of one dose of the SARS-CoV-2 variant (Omicron BA.5) mRNA vaccine in people aged 18…
- Trial name
- NCT05745545
- Testing
- SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine, Saline solution
- Where
- China
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
18 Years and Over, Newborn Health
Multıdımensıonal Effects Of Delayed Cord Clampıng and Mılkıng on Placental Processes
This study was conducted to evaluate the effects of delayed cord clamping and milking the umbilical cord of term babies after 90 seconds during vaginal birth on the newborn and the mother and to determine whether it is a suitable…
- Conditions
- 18 Years and Over, Newborn Health, 37 or More Completed Weeks of Gestation
- Trial name
- DCC&MILKHEM P (NCT06865391)
- Testing
- Delayed cord clamping
- Where
- Turkey (Türkiye)
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Kahramanmaras Sutcu Imam University
Over 18 Years Old
Effects of Kinesio Taping on Premenstrual Syndrome
This randomized, single-blind study aimed to evaluate the effects of kinesio taping on PMS symptoms, happiness, and quality of life.
- Trial name
- NCT07155720
- Testing
- Intervention (Kinesio Taping) group
- Where
- Turkey (Türkiye)
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Yağmur SÜRMELİ AKBAL
Influenza, Human
Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years
This study is designed to test the safety and immunogenicity of Fluviral® (2009 - 2010 Season) in adults aged 18 to 60 years and over 60 years.
- Trial name
- NCT00929331
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)
Popular topic:A Clinical Study of Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) Overall design:The study was designed as a randomized, open and controlled study.
- Trial name
- NCT05574985
- Testing
- Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell), Inactivated COVID-19 vaccine (Vero Cell)
- Where
- China
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Vaginal Infection
Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463
The purpose of this study is to determine the safety, local tolerability and pharmacokinetic parameters of TOL-463 intravaginal dosage forms in both healthy, nonpregnant females following single dose administration (Part 1), and…
- Trial name
- NCT01812889
- Testing
- TOL-463 Vaginal ovule, TOL-463 Vaginal gel
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old
This is an open study of the use of AdimFlu-S (2010-2011 season) vaccine in young subjects aged between 6 months old to 18 years old. All participants will be divided into three age cohorts.
- Trial name
- NCT01356342
- Testing
- AdimFlu-S 2010-2011, inactivated
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Influenza
Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population
This is a laboratory-blinded study in healthy toddlers, children, and teenagers designed to investigate the safety, reactogenicity, and immunogenicity of an inactivated influenza H1N1 vaccine (AdimFlu-S).
- Trial name
- NCT01007201
- Testing
- Influenza A (H1N1) 2009 monovalent vaccine, inactivated
- Where
- 2 sites in Taiwan
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Influenza
An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older
The primary efficacy objective is to demonstrate the efficacy of aCoV2 versus a placebo to prevent the first occurrence of virologically-confirmed symptomatic COVID 19 according to the European Centre for Disease Prevention and…
- Trial name
- NCT04806529
- Testing
- Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2), Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine
Vaccination is currently the most effective means of controlling influenza and preventing its complications and mortality in persons at risk.
- Trial name
- NCT00505453
- Testing
- Fluviral®
- Where
- 2 sites in Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
SARS-CoV2, Covid19
A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults
This study is being conducted to look at the safety and immune response (how the immune system of the human body reacts) to a vaccine for SARS-CoV-2 (the virus responsible for COVID-19 infection) when administered as an…
- Trial name
- NCT04495933
- Testing
- MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
- Where
- Australia
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
Influenza Vaccines
Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years
This study will evaluate the immunogenicity and safety of GSK Biologicals' Trivalent split virion influenza vaccine Fluviral for the 2008-2009 season in adults over the age of 18.
- Trial name
- NCT00718120
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03
This is a comparative vaccination study of the reactogenicity and immunogenicity of a thiomersal-free formulation of Influsplit SSW® 2002/2003 versus the standard formulation of Influsplit SSW® 2002/2003 in individuals over 18…
- Trial name
- NCT00731029
- Testing
- Thiomersal free trivalent influenza split vaccine 2002/2003, GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003
- Where
- Germany
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Contraception
FC Patch Low: Metabolism Study
The aim of the present study is to investigate the effects of the transdermal patch on the parameters of hemostasis (blood clotting), lipid (fat), and carbohydrate (sugars) metabolism in healthy women who require contraception.
- Trial name
- NCT00933179
- Testing
- Gestodene/EE Patch (BAY86-5016), EE/Levonorgestrel (Microgynon, BAY86-4977)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
SARS-CoV-2
A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People
This is a cohort study to evaluate safety and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China
- Trial name
- NCT05549206
- Testing
- SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
Influenza
Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults
The purpose of this trial is to describe the immunogenicity, the safety, and tolerability of FluLaval™ TR and Fluarix®, the latter serving as active comparator.
- Trial name
- NCT00380211
- Testing
- Influenza vaccine (A/H3N2, A/H1N1, and B strains), Fluarix
- Where
- 6 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 Years
The aim of the study is to investigate the safety and immunogenicity of the RSV/Flu-01E vaccine for the prevention of respiratory syncytial virus infection in volunteers aged18 to 59 years and over 60 years.
- Trial name
- NCT05970744
- Testing
- RSV/Flu-01E low dose, RSV/Flu-01E high dose
- Where
- Russia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tatyana Zubkova
Influenza
Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years
This study is designed to test the safety and immunogenicity of Fluviral® (2010 - 2011 Season) in adults aged 18 to 60 years and over 60 years.
- Trial name
- NCT01153685
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline